164 related articles for article (PubMed ID: 10587975)
21. Primary tumor control in patients with stage 3/4 unfavorable neuroblastoma treated with tandem double autologous stem cell transplants.
Marcus KJ; Shamberger R; Litman H; von Allmen D; Grupp SA; Nancarrow CM; Goldwein J; Grier HE; Diller L
J Pediatr Hematol Oncol; 2003 Dec; 25(12):934-40. PubMed ID: 14663275
[TBL] [Abstract][Full Text] [Related]
22. Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma.
Illhardt T; Toporski J; Feuchtinger T; Turkiewicz D; Teltschik HM; Ebinger M; Schwarze CP; Holzer U; Lode HN; Albert MH; Gruhn B; Urban C; Dykes JH; Teuffel O; Schumm M; Handgretinger R; Lang P
Biol Blood Marrow Transplant; 2018 May; 24(5):1005-1012. PubMed ID: 29307718
[TBL] [Abstract][Full Text] [Related]
23. Thiotepa and cyclophosphamide with stem cell rescue for consolidation therapy for children with high-risk neuroblastoma: a phase I/II study of the Pediatric Blood and Marrow Transplant Consortium.
Kletzel M; Abella EM; Sandler ES; Williams LL; Ogden AK; Pollock BH; Wall DA
J Pediatr Hematol Oncol; 1998; 20(1):49-54. PubMed ID: 9482413
[TBL] [Abstract][Full Text] [Related]
24. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study.
Seeger RC; Reynolds CP; Gallego R; Stram DO; Gerbing RB; Matthay KK
J Clin Oncol; 2000 Dec; 18(24):4067-76. PubMed ID: 11118468
[TBL] [Abstract][Full Text] [Related]
25. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry.
Ladenstein R; Philip T; Lasset C; Hartmann O; Garaventa A; Pinkerton R; Michon J; Pritchard J; Klingebiel T; Kremens B; Pearson A; Coze C; Paolucci P; Frappaz D; Gadner H; Chauvin F
J Clin Oncol; 1998 Mar; 16(3):953-65. PubMed ID: 9508178
[TBL] [Abstract][Full Text] [Related]
26. Long-term results of high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma patients: a report of the Spanish working party for BMT in children (Getmon).
Verdeguer A; Muñoz A; Cañete A; Pardo N; Martínez A; Donat J; Gómez P; Bureo E; Fernández JM; Cubells J; Maldonado M; Sastre A
Pediatr Hematol Oncol; 2004 Sep; 21(6):495-504. PubMed ID: 15552813
[TBL] [Abstract][Full Text] [Related]
27. [Comprehensive protocol for diagnosis and treatment of childhood neuroblastoma--results of 45 cases].
Tang JY; Pan C; Chen J; Xu M; Chen J; Xue HL; Gu LJ; Dong R; Ye H; Zhou M; Wang YP
Zhonghua Er Ke Za Zhi; 2006 Oct; 44(10):770-3. PubMed ID: 17229383
[TBL] [Abstract][Full Text] [Related]
28. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
London WB; Bagatell R; Weigel BJ; Fox E; Guo D; Van Ryn C; Naranjo A; Park JR
Cancer; 2017 Dec; 123(24):4914-4923. PubMed ID: 28885700
[TBL] [Abstract][Full Text] [Related]
29. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
30. Detection and treatment of minimal residual disease in high-risk neuroblastoma.
Reynolds CP
Pediatr Transplant; 2004 Jun; 8 Suppl 5():56-66. PubMed ID: 15125707
[TBL] [Abstract][Full Text] [Related]
31. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study.
Kletzel M; Katzenstein HM; Haut PR; Yu AL; Morgan E; Reynolds M; Geissler G; Marymount MH; Liu D; Kalapurakal JA; Shore RM; Bardo DM; Schmoldt J; Rademaker AW; Cohn SL
J Clin Oncol; 2002 May; 20(9):2284-92. PubMed ID: 11980999
[TBL] [Abstract][Full Text] [Related]
32. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.
Kushner BH; Cheung IY; Kramer K; Modak S; Cheung NK
Pediatr Blood Cancer; 2007 Apr; 48(4):430-4. PubMed ID: 16421906
[TBL] [Abstract][Full Text] [Related]
33. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.
Kaneko M; Tsuchida Y; Mugishima H; Ohnuma N; Yamamoto K; Kawa K; Iwafuchi M; Sawada T; Suita S
J Pediatr Hematol Oncol; 2002 Nov; 24(8):613-21. PubMed ID: 12439032
[TBL] [Abstract][Full Text] [Related]
34. In vivo purging of bone marrow in children with poor-risk neuroblastoma for marrow collection and autologous bone marrow transplantation.
Saarinen UM; Wikström S; Mäkipernaa A; Lanning M; Perkkiö M; Hovi L; Rapola J; Sariola H
J Clin Oncol; 1996 Oct; 14(10):2791-802. PubMed ID: 8874341
[TBL] [Abstract][Full Text] [Related]
35. [High-dose chemotherapy and hematopoietic stem cell transplant in the treatment of advanced neuroblastoma].
Mugishima H
Gan To Kagaku Ryoho; 1999 Jul; 26(8):1056-67. PubMed ID: 10431577
[TBL] [Abstract][Full Text] [Related]
36. Commentary on Kaneko et al.: Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.
Brodeur GM
J Pediatr Hematol Oncol; 2002 Nov; 24(8):608-9. PubMed ID: 12439030
[No Abstract] [Full Text] [Related]
37. [Myeloablative chemotherapy with autologous bone marrow and/or peripheral blood stem cell transplantation in children with high-risk solid tumor].
Endo M; Tanosaki R
Gan To Kagaku Ryoho; 1995 Oct; 22(12):1762-70. PubMed ID: 7574807
[TBL] [Abstract][Full Text] [Related]
38. Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma.
Burchill SA; Kinsey SE; Picton S; Roberts P; Pinkerton CR; Selby P; Lewis IJ
Med Pediatr Oncol; 2001 Jan; 36(1):213-9. PubMed ID: 11464888
[TBL] [Abstract][Full Text] [Related]
39. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.
Molina B; Alonso L; Gonzalez-Vicent M; Andion M; Hernandez C; Lassaletta A; Cormenzana M; Lopez-Ibor B; Villa M; Molina J; Diaz MA
Pediatr Hematol Oncol; 2011 Mar; 28(2):115-23. PubMed ID: 21299340
[TBL] [Abstract][Full Text] [Related]
40. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma.
Yanik GA; Levine JE; Matthay KK; Sisson JC; Shulkin BL; Shapiro B; Hubers D; Spalding S; Braun T; Ferrara JL; Hutchinson RJ
J Clin Oncol; 2002 Apr; 20(8):2142-9. PubMed ID: 11956276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
